drugset / Trial / NCT04830020
Use of Inhaled High-molecular Weight Hyaluronan in Patients With Severe COVID19: Feasibility and Outcomes
Phase 2
Completed
180 enrolled
Campus-Bio-Medico University
National Institute of Environmental Health Sciences (NIEHS) · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
To determine whether inhaled Yabro protects against progression of COVID19-induced respiratory failure preventing the passage to non-invasive ventilation (NIV) and promotes recovery from COVID19 lung disease in hospitalized patients.
Timeline
- Start
- 2021-02-26
- Primary completion
- 2021-06-30
- Completion
- 2021-09-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | HMW-HA | Other / unclassified | 0.3 % | Other |
| Comparator | HMW-HA | Other / unclassified | 5 ml | Other |